BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,259,028 | +15.8% | 312,311 | +38.9% | 0.01% | +25.0% |
| Q2 2023 | $18,354,203 | +16.7% | 224,846 | +6.0% | 0.01% | 0.0% |
| Q1 2023 | $15,733,810 | -10.1% | 212,075 | +0.4% | 0.01% | -11.1% |
| Q4 2022 | $17,510,235 | +20.7% | 211,272 | +313.5% | 0.01% | +12.5% |
| Q3 2022 | $14,510,000 | -18.1% | 51,091 | -0.0% | 0.01% | -20.0% |
| Q2 2022 | $17,710,000 | -23.2% | 51,092 | -4.1% | 0.01% | -16.7% |
| Q1 2022 | $23,059,000 | -24.0% | 53,250 | -9.2% | 0.01% | -20.0% |
| Q4 2021 | $30,347,000 | +8.3% | 58,660 | +1.4% | 0.02% | 0.0% |
| Q3 2021 | $28,025,000 | +11.8% | 57,834 | +3.9% | 0.02% | +7.1% |
| Q2 2021 | $25,069,000 | +21.7% | 55,677 | +3.3% | 0.01% | +7.7% |
| Q1 2021 | $20,591,000 | +45.2% | 53,914 | +20.7% | 0.01% | +18.2% |
| Q4 2020 | $14,186,000 | +48.7% | 44,674 | +16.0% | 0.01% | +37.5% |
| Q3 2020 | $9,543,000 | +16.3% | 38,521 | +24.0% | 0.01% | 0.0% |
| Q2 2020 | $8,203,000 | +50.5% | 31,063 | +8.0% | 0.01% | +33.3% |
| Q1 2020 | $5,451,000 | -3.6% | 28,749 | +11.6% | 0.01% | 0.0% |
| Q4 2019 | $5,657,000 | +20.3% | 25,772 | +7.2% | 0.01% | +20.0% |
| Q3 2019 | $4,703,000 | +3.7% | 24,038 | +10.5% | 0.01% | -16.7% |
| Q2 2019 | $4,535,000 | +10.3% | 21,753 | +5.1% | 0.01% | 0.0% |
| Q1 2019 | $4,111,000 | +59.3% | 20,707 | +16.2% | 0.01% | +50.0% |
| Q4 2018 | $2,580,000 | +77.9% | 17,827 | +82.0% | 0.00% | +33.3% |
| Q2 2018 | $1,450,000 | -0.1% | 9,796 | +1.9% | 0.00% | -25.0% |
| Q1 2018 | $1,452,000 | +13.4% | 9,616 | -2.7% | 0.00% | +33.3% |
| Q4 2017 | $1,280,000 | +9.5% | 9,878 | +2.2% | 0.00% | 0.0% |
| Q3 2017 | $1,169,000 | -13.8% | 9,665 | -16.2% | 0.00% | -25.0% |
| Q2 2017 | $1,356,000 | +18.7% | 11,536 | +2.4% | 0.00% | 0.0% |
| Q1 2017 | $1,142,000 | +3.2% | 11,263 | +4.4% | 0.00% | 0.0% |
| Q4 2016 | $1,107,000 | -5.7% | 10,785 | +0.6% | 0.00% | -20.0% |
| Q3 2016 | $1,174,000 | -46.4% | 10,722 | -44.8% | 0.01% | -44.4% |
| Q2 2016 | $2,192,000 | +17.2% | 19,436 | -1.8% | 0.01% | +12.5% |
| Q1 2016 | $1,870,000 | +0.7% | 19,784 | -4.1% | 0.01% | 0.0% |
| Q4 2015 | $1,857,000 | -2.7% | 20,629 | -0.1% | 0.01% | -11.1% |
| Q3 2015 | $1,909,000 | -1.2% | 20,651 | +5.2% | 0.01% | 0.0% |
| Q2 2015 | $1,933,000 | – | 19,633 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |